Chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer (NSCLC). This treatment, however, offers only a small chance of cure and is associated with many side effects. Little research has been made concerning which patients benefit most/least from the treatment. The present study evaluates the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in this treatment setting. In the present study, data were collected retrospectively for 222 patients from two different phase II studies conducted between 2002-2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC. Clinical data and the serum values of hemoglobin (Hgb), White blood cells (WBC) and Platelets (Plt) at enrollment were collected for all patients and studied in relation to overall survival using Kaplan-Meier product-limit estimates and a multivariate Cox proportional hazards regression model. The results showed that patients with thrombocytosis (Plt > 350 x 10 9 /L) had a shorter median overall survival (14.5 months) than patients with normal Plt at baseline (23.7 months). Patients with leukocytosis (WBC > 9 x 10 9 /L) had a shorter median survival (14.9 months) than patients with a normal WBC at baseline (22.5 months). However, in a multivariate model including all lab parameters and clinical factors, only thrombocytosis and performance status displayed a prognostic significance. In Conclusion, thrombocytosis showed to be an independent prognostic marker associated with shorter overall survival in stage III NSCLC treated with curatively intended chemoradiotherapy. This knowledge can potentially be used together with established prognostic factors, such as performance status when choosing the optimal therapy for the individual patient in this clinical setting.
Lung cancer is the leading cause of cancer-related death worldwide [1] . Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for about 85 % of all cases [2] . The prognosis for these patients is poor, partly due to the fact that most patients are diagnosed in a late stage of disease when the tumor has become inoperable. Patients with locally advanced NSCLC (stage III) in a good performance status are usually treated with a combination of radiotherapy and chemotherapy, a treatment with a curative intention but also with considerable and potentially fatal side effects [3, 4] . Despite receiving this treatment, the 5-year survival rate for stage III NSCLC is only about 15 % [5] . In this situation, the challenge for the clinician is to give the best possible treatment to each individual patient and to avoid unnecessary side effects. Many studies have been conducted concerning prognostic and predictive biomarkers, often driven by the development of biological anti-neoplastic drugs [6] . However, little research has been done concerning clinical prognostic and predictive markers in radical radiotherapy, despite the great need to identify which patients will benefit from this kind of treatment. The Swedish Lung Cancer Study Group has previously conducted retrospective studies of a large cohort of NSCLC patients searching for clinical prognostic factors in NSCLC treated with curatively intended radiotherapy [7] [8] [9] with results indicating that anemia, leukocytosis and thrombocytosis at diagnosis are negative prognostic markers associated with shorter overall survival [9] . The role of these hematopoietic markers in NSCLC has been reviewed elsewhere in the literature, but with conflicting results and in heterogeneous study populations [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The aim of the present study was to retrospectively assess the prognostic value of anemia, leukocytosis and thrombocytosis at diagnosis in two cohorts of patients with stage III NSCLC treated with curatively intended chemoradiotherapy between the years 2002-2007 in Sweden.
Patients and methods
Data were collected retrospectively from two different phase II studies evaluating radiotherapy in stage III NSCLC conducted between the years 2002-2007 in Sweden. The first study, the RAKET trial [22] , was a three-armed randomized trial of 151 patients with NSCLC stage IIIA/IIIB treated with induction chemotherapy (carboplatin AUC 6/paclitaxel 200 mg/m 2 ) followed by either A, hyperfractionated accelerated radiotherapy 1.7 Gy twice-a-day to 64.6 Gy concurrent with a third cycle chemotherapy, B, radiotherapy with 2 Gy daily to 60 Gy concurrent with daily paclitaxel 12 mg/m 2 , or C, radiotherapy with 2 Gy daily to 60 Gy concurrent with weekly paclitaxel 60 mg/m 2 . The second study, the Satellite trial [23] , was a one-armed phase II trial of 71 patients with NSCLC stage IIIA/IIIB treated with two cycles of induction chemotherapy (cisplatin 75 mg/m 2 /docetaxel 75 mg/m 2 ) followed by radiotherapy, 2 Gy daily, to 68 Gy concurrent with weekly cetuximab (initial dose of 400 mg/m 2 followed by 250 mg/m 2 ). In total these trials compose a pooled dataset of 222 patients available for analysis. Data regarding gender, age at diagnosis, histology (defined as squamous cell carcinoma, adenocarcinoma or other non-small cell lung cancer), performance status, weight loss, stage and the serum values of hemoglobin (Hgb), white blood cells (WBC) and platelets (Plt) at enrollment were collected for all patients and studied in relation to overall survival. The reference limits for thrombocytosis (Plt > 350 x 10 9 /L) and leukocytosis (WBC > 9 x 10 9 /L) were taken from the normal intervals used at the Uppsala University Hospital. The lower Hgb limit is different in men and women. However, we decided to use < 110 g/L as the limit for anemia in both genders as have been done previously [9] .
Statistics. Standard descriptive statistics were used to present patients' characteristics at diagnosis. Overall survival was analyzed with Kaplan-Meier product-limit estimates and survival curves for the different categories of patients were compared using the log-rank test. Follow-up time was calculated from the date of enrollment to the date of death or last follow-up date. Age was defined as age at diagnosis and categorized into age groups as have been reported previously [8] as well as analyzed as a variable. Overall survival was also analyzed using a multivariate Cox proportional hazards regression model. The multivariate model was adjusted by gender, age at diagnosis, Hgb, WBC and Plt. Results were presented as hazard ratios with 95 % confidence intervals (95 % CI) and with p-values where p < 0.05 was considered statistically significant.
Results
Of the 222 patients available for analysis, 113 (51%) were men. The median age was 62 years (range: 42 -81 years). Histologically, 107 patients (48%) had adenocarcinoma (AC), 75 patients (34%) had squamous cell carcinoma (SCC) and The median overall survival for all patients was 17.7 months and the median survival was similar in the RAKET study, 17.8 months, as compared with the Satellite study, 17.0 months. Male patients had a tendency towards shorter median overall survival than female patients (15.8 vs. 20.6 months), a difference that was not statistically significant (p = 0.11, log-rank test). Patients with AC histology had a median overall survival of 20.1 months which was superior to patients with SCC and other histology (18.2 and 13.0 months, respectively), a difference which was not statistically significant (p = 0.099, log-rank test). Patients with PS 0 had a better median overall survival than patients with PS 1 (22.5 and 14.9 months, respectively), a difference which was statistically significant (p = 0.0015, log-rank test). Patients in disease stage IIIB had a slightly better overall survival than Figure 1 . Hematopoietic lab abnormalities and survival patients in stage IIIA (17.9 and 16.4 months, respectively), but the difference was not statistically significant (p = 0.68, log-rank test). Patients with pre-treatment weight loss of >5% had a shorter median survival than patients with weight loss ≤5 % (13.6 and 20.6 months, respectively), a difference that did not reach statistical significance (p = 0.061, log-rank test).
When comparing patients with and without anemia ( Figure 1A ), the patients with anemia had a shorter median survival (12.5 months) as compared with the patients without anemia (18.2 months). The difference was not statistically significant (p = 0.39, log rank test). For patients with and without leukocytosis ( Figure 1B ), the patients with leukocytosis had a shorter median survival (14.9 months) as compared with the patients with a normal WBC at baseline (22.5 months). The difference was statistically significant (p = 0.016, log rank test). Furthermore, for patients with and without thrombocytosis ( Figure 1C ), the patients with thrombocytosis had a shorter median survival (14.5 months) as compared with the patients with normal Plt at baseline (23.7 months). The difference was statistically significant (p = 0.0025, log rank test). For a summary of median overall survival in different categories of patients see Table 2 . It was found that the values of WBC and Plt correlated with a Spearman's correlation coefficient of 0.44 (p<0.0001) meaning that patients with high WBC levels were more likely to also have high Plt levels ( Figure 2) . Also, as shown in Figure 3 , higher Plt levels were seen in patients with PS 1 as compared with patients with PS 0 (p = 0.037, Mann-Whitney's test). In a multivariate Cox analysis (Table 3) including clinical data and all three pathological lab parameters the prognostic significance was still evident for PS (HR: 1.61, 95% CI: 1.15-2.26, p = 0.0051) and thrombocytosis (HR: 1.66, 95% CI: 1.12-2.48, p = 0.012) whereas leukocytosis was no longer significantly associated with worse overall survival (HR: 1.09, 95% CI: 0.75-1.58, p = 0.64). Due to missing data, 11 patients were excluded from the multivariate analysis. 
Discussion
In the present study we have analyzed the relationship between the standard hematopoietic blood parameters Hgb, WBC and Plt at diagnosis and overall survival in two cohorts including 222 patients with NSCLC treated with curatively intended chemoradiotherapy. Our findings show that there is a statistically significant independent association between thrombocytosis at diagnosis and shorter overall survival in both univariate and multivariate analyses. The negative prognostic impact of thrombocytosis on survival is comparable with having a WHO Performance status of 1 as compared with PS 0. For leukocytosis a similar relationship is seen in a univariate analysis but not in a multivariate analysis when other factors such as performance status are taken into consideration. For anemia, no relationship with survival is found although the results are difficult to interpret due to the low number of patients with anemia in the two cohorts.
The prognostic value of standard hematopoietic blood parameters in NSCLC has received scant interest and many of the previous studies included small and heterogeneous study populations. The strengths of the present study are the relatively large number of clearly defined and similarly treated patients; stage III NSCLC in good performance status (0-1) treated with curatively intended chemoradiotherapy. However, the study also has some limitations including its retrospective nature and that the data come from two separate cohorts with slightly differently treated patient populations. Also, stage III NSCLC consists of a heterogeneous population of lesions (i.e., T4N0-3, T3N1-3, and T1a-2aN2-3) and the prognostic significance of the blood parameters examined may differ between these entities. Furthermore, other factors affecting the values of the examined hematopoietic blood parameters such as infections, inflammatory diseases and medications have not been taken into consideration.
A mechanism of elevated thrombocyte count affecting the blood vessel endothelium leading to facilitation of cell invasion and metastasis has been suggested [24] and thrombocytosis has, similarly to leukocytosis, been shown to be a negative prognostic marker in NSCLC in several studies [12, [16] [17] [18] [19] [20] . Lately, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have been shown to be a prognostic factor for survival in several solid tumors, including NSCLC [25, 26] . In a study by Unal et al. of 94 patients with non-metastatic NSCLC who underwent chemoradiotherapy, pretreatment high NLR and PLR were both associated with shorter disease-free and overall survival rates. In a multivariate analysis, overall survival was significantly associated with high PLR whereas disease-free survival was significantly associated with high NLR [27] . In a retrospective study of 59 patients with stage I NSCLC treated with stereotactic radiotherapy, high PLR was significantly associated with a higher non-local failure rate as compared with low PLR in a multivariate analysis (58% as compared with 11%) [28] .
The impact of pretreatment anemia for NSCLC patients is controversial. In accordance with the present study, the results from a large study of over 2500 NSCLC patients by Albain et al. [29] showed no correlation between anemia and survival in the entire NSCLC population. However, there are also some reports of pre-treatment low Hgb as an independent prognostic factor for survival in NSCLC [30, 31] . Leukocytosis in patients with cancer is usually caused by infection or bone marrow metastases. However, in some cases elevated WBC is seen in absence of other signs of infectious disease and is considered to be paraneoplastic, caused mainly by abnormal production of hematopoietic cytokines by the tumor of which more than 40 have been identified to this date [32] . Several studies, including a pooled analysis of North Central Cancer Treatment Group (NCCTG) trials with data from over 1000 patients, have reported leukocytosis to be associated with poorer outcome in NSCLC [12, 14, 15, 21, 31] .
However, previous studies have either been focused on advanced/metastatic NSCLC or leukocytosis and thrombocytosis have not been analyzed together in multivariate models that include established prognostic factors such as performance status. Thus, their prognostic significance in the setting of curatively intended chemoradiotherapy for NSCLC remains unclear. Notably, in the present study leukocytosis was shown to be a prognostic marker of shorter overall survival when analyzed on its own but not when other factors such as thrombocytosis and performance status were taken into account in a multivariate analysis. Considering the high correlation between leukocytosis and thrombocytosis, it is possible to hypothesize that leukocytosis is associated with thrombocytosis as a marker of inflammation, but leukocytosis per se is not associated with worse prognosis in NSCLC. Interestingly, while thrombocytosis also correlates with worse performance status, both factors are independently associated with shorter median survival with similar hazard ratios in a multivariate analysis.
In conclusion, of the three standard hematopoietic lab abnormalities studied here, thrombocytosis seems to have the highest prognostic significance and to be associated with shorter overall survival in stage III NSCLC treated with curatively intended chemoradiotherapy. Further studies are required to fully assess the prognostic value of thrombocytosis and to find ways to integrate it with established prognostic factors such as performance status and disease stage, when choosing the optimal therapy for the individual patient.
